Mylan’s Commitment to Oncology

At Mylan, we have and are continuing to build a comprehensive portfolio of therapies and diagnostics and nowhere is that more evident than in our growing catalog of oncology products.

From diagnosis and treatment to supportive care, Mylan is committed to offering you and your patients the oncology and diagnostic agents that meet the demands of an ever-changing healthcare landscape. We strive to provide the more than 11,000 U.S. oncology partners with a comprehensive list of diagnosis, treatment and supportive care agents.

See how our breadth, manufacturing capabilities and strong partnerships combine to allow Mylan to be there for you, your team and your patients.

Sign up to stay informed about Mylan in Oncology >

From two oncology treatments to more than 20
in just five years

That’s just a start.

Five years ago, Mylan offered only two oncology treatments. That number has grown more than 10-fold. And we’re not stopping.*

From solid tumors, such as breast, lung, colon and prostate, to lymphomas and leukemias, Mylan offers a wide range of chemotherapy agents. Those therapies are included as Category 1 agents in more than 30 NCCN® clinical practice guidelines.

Our portfolio includes more than just chemotherapy.

We offer products for every stage of cancer survivorship, to help stage disease and supportive care therapies that lessen the side effects of cancer treatments.2

And our growth will continue. We have a strong pipeline that contains more chemotherapy agents, the backbone of cancer care, as well as newer and more advanced product categories.*

Through innovation, we are committed to doing what's right, not what's easy—producing difficult-to-manufacture products, formulations and preparations.

Learn more about Mylan’s oncology product manufacturing capacity >

Get Updates on Mylan's Commitment to Oncology

See Pink. Think Blue.

Mylan is committed to helping healthcare providers diagnose and treat breast cancer. See how

Mylan Product Catalog

View our complete Product Portfolio

View now

11 million dosing units may seem like a lot

But we’re still doing more.

Last year, Mylan manufactured more than 11 million dosing units of chemotherapy, supportive therapies and diagnostics for treating patients and managing their cancer.

At Mylan, we’re committed to providing cancer care specialists with a comprehensive inventory of oncology products for all stages of cancer survivorship. From vials and prefilled syringes to oral doses, Mylan offers oncology products in a wide range of delivery forms.

To keep up with our broad portfolio, we have grown our production facilities to now include approximately 50 state-of-the-art manufacturing sites around the globe, including 9 that manufacture injectables agents such as chemotherapy.

We understand that critical difficult-to-manufacture therapies such as chemotherapies, are needed in the marketplace. Mylan has the capacity and capability to provide you with the necessary difficult-to-manufacture oncology products you need to provide seamless care—one patient at a time.

Learn more about our commitment to cancer care >

Get Updates on Mylan's Commitment to Oncology

See Pink. Think Blue.

Mylan is committed to helping healthcare providers diagnose and treat breast cancer. See how

Mylan Product Catalog

View our complete Product Portfolio

View now

Let us help you treat the 1.6 million patients
diagnosed with cancer1

What drives you in helping your patients with cancer?

Every patient matters. That is why Mylan supports cancer care specialists by providing an oncology portfolio for patients in need.

We understand and share your commitment to providing seamless patient care. That’s why we are building one of the largest generic oncology portfolios in the US. Helping patients with cancer battle their disease is the reason we offer more than 20 chemotherapy agents.

And because we have that same goal, you can be assured that we have plans to add numerous products over the next several years to help your patients at every stage of cancer survivorship. By 2018, we will nearly double our number of injectables products* with you and your patients in mind.

Mylan in Oncology is a partnership between us and the more than 11,000 care providers in the United States who depend on our breadth of offerings and commitment to cancer care.

Learn more about our growing oncology portfolio >

Get Updates on Mylan's Commitment to Oncology

See Pink. Think Blue.

Mylan is committed to helping healthcare providers diagnose and treat breast cancer. See how

Mylan Product Catalog

View our complete Product Portfolio

View now

  • Mylan in Oncology updates sent right to your inbox

    Stay up to date with news and product updates from Mylan.

    Register for email alerts >

*The foregoing contains a forward-looking statement concerning the Company’s projection of product launches by 2018. This forward-looking statement is made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because this forward-looking statement inherently involves risks and uncertainties, actual future results may differ materially from those expressed or implied by such statement. The Company undertakes no obligation to update this forward-looking statement.

To view the most recent and complete versions of the guidelines, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN® Content are trademarks owned by the National Comprehensive Cancer Network, Inc.

An individual is considered a cancer survivor from the time of diagnosis through the balance of his or her life.

References: 1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Georgia; American Cancer Society; 2016.
2.
National Comprehensive Cancer Network. Survivorship v.2.2015 [September 8, 2015]. Fort Washington, PA: NCCN; 2015.